Sudhin Biopharma — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Founded in 2018, Sudhin Biopharma is a private, pre-revenue biotech firm leveraging its proprietary BioSettler technology platform. The platform is a single-use, inclined settling device designed for selective cell retention, clarification, and product recovery in biomanufacturing processes for biologics and cell therapies. While the company's stated mission is to develop novel cancer therapies, current public information heavily emphasizes the BioSettler's role as an enabling tool for bioprocessing, suggesting a potential dual focus on platform technology and therapeutic development.

Oncology

Technology Platform

Sudhin BioSettler: a single-use, inclined settling device for selective cell retention, clarification, and product recovery in biomanufacturing processes. Applications include perfusion bioreactor cell retention, clarification of cell culture broth for products like antibodies and AAV vectors, harvesting/washing/concentration of cell therapies (CAR-T, islet cells), and in situ product recovery via oil-water emulsion separation.

Opportunities

The growing demand for efficient, gentle, and scalable bioprocessing solutions for biologics and cell therapies presents a major opportunity for the BioSettler platform.

Successfully partnering with biopharma companies or CDMOs could provide validation and revenue.

Applying the platform to manufacture its own cell-based oncology therapies could create significant long-term value.

Risk Factors

Key risks include unproven technology performance at commercial scale, unclear strategic focus between platform and therapeutic development, intense competition in both bioprocessing and oncology, and the significant funding required to advance its programs.

Competitive Landscape

In bioprocessing, the BioSettler competes with established centrifugation, filtration, and acoustic wave separation technologies from large corporations. In therapeutic development, it would compete with hundreds of oncology-focused biotechs and pharma companies. Its differentiation lies in the simplicity and potential gentleness of the inclined settling method for sensitive cells.

More companies in Small Molecule Drugs →More companies in United States →